Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Instituto Valenciano de Oncologia, Valencia, Spain apoveda@fivo.org.
Andres M
AM
Poveda
Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens (GINECO), University Pierre et Marie Curie-Sorbonne, Tenon Hospital, Hôpitaux Universitaires de l'Est Parisien-Assistance Publique-Hôpitaux de Paris, and Alliance Pour la Recherche en Cancérologie, Paris, France.
Frédéric
F
Selle
Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) and Klinik für Gynäkologie und Geburtshilfe, Kiel, Germany.
Felix
F
Hilpert
AGO and Coordinating Center for Clinical Trials, Marburg, Germany.
Alexander
A
Reuss
Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies and Regina Elena National Cancer Institute, Rome, Italy.
Antonella
A
Savarese
Belgian Gynaecological Oncology Group and University Hospital Leuven, Leuven, Belgium.
Ignace
I
Vergote
Dutch Gynaecological Oncology Group and University Medical Center Utrecht, Utrecht, the Netherlands.
Petronella
P
Witteveen
Hellenic Cooperative Oncology Group and University of Athens, Athens, Greece.
Aristotelis
A
Bamias
F. Hoffmann-La Roche, Basel, Switzerland.
Nana
N
Scotto
F. Hoffmann-La Roche, Basel, Switzerland.
Lada
L
Mitchell
GINECO and Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France.
Eric
E
Pujade-Lauraine
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D060787:Neoplasm Grading; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D017239:Paclitaxel / Q000008:administration & dosage; D017671:Platinum Compounds / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011379:Prognosis; D012307:Risk Factors; D019772:Topotecan / Q000008:administration & dosage; D016896:Treatment Outcome
D017671:Platinum Compounds; C506643:liposomal doxorubicin; D000068258:Bevacizumab; D011092:Polyethylene Glycols; D019772:Topotecan; D004317:Doxorubicin; D017239:Paclitaxel